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Abstract- Pain is one of the most common and often most 
feared symptoms in patients with cancer. Ongoing or 
progressive pain is physically debilitating and has a 
marked impact on quality of life. During their illness, at 
least 70% of patients will experience pain sufficiently 
severe to require chronic opioid treatment. Moreover, 
Breakthrough Pain (BTP) consists in transitory 
exacerbations of pain that occurs on a background of 
otherwise stable pain in a patient receiving chronic opioid 
therapy. An inadequate baseline therapy with opioids can 
be one of the causes of BTP.  
We will examine the molecular issues that influence the 
response of patients to opioids. Finally, we will discuss 
about the importance of individualizing therapy. 
 
 







I.  INTRODUCTION 
Cancer-induced pain is usually described under 3 
headings: acute pain, chronic pain and Breakthrough Pain 
(BTP). Acute pain, for example, may result from the 
pathologic fractures that occur when tumors invade bone. 
One form of chronic pain may occur when cancer directly 
invades nerves causing severe neuropathic pain [1,2].  
BTP consists in transitory exacerbations of pain that 
occurs on a background of stable pain controlled by 
baseline opioid regimen. BTP characteristically reaches 
peak intensity within a matter of minutes, requiring 
treatment with a rapidly acting, potent opioid.  
Clinical definitions of  BTP have been further refined by 
distinguishing between the following [3]: 
- incident, predictable pain: a consistent temporal 
causal relationship with a predictable motor 
activity such as movement, defecation, urination 
or breathing; 
- incident, unpredictable pain: an inconsistent 






- idiopatic pain: not associated with a known 
cause and usually of longer duration compared 
with incident pain; 
- procedural pain: pain related to a therapeutic 
intervention such as dressing a wound; 
Some authors in the past also described the end-of-dose 
BTP as pain occurring before a scheduled dose of an 
around-the-clock analgesic. However, it is not properly a  
subtype of BTP, because this pain is frequently related to 
underdose of the opioids used for baseline therapy and it 
more often occurs during titration phase. 
With respect to analgesics, the World Health Organization 
(WHO) has devoloped a 3-step “analgesic ladder” to 
guide management of cancer pain [4], based on the pain’s  
severity, estimated by use of a 1 to 10 numeric rating 
scale [Table I]. 
 
                                             Table I:  





For treatment of BTP, there is a need for rapidly acting, 
powerful “rescue” analgesic. Intravenous morphine has 
been used for this purpose  with reported success. 
However, fentanyl seems to be preferable for treatment of 
BTP. Because of its low molecular weight and lipid 
solubility, fentanyl is well suited for delivery via  
transmucosal or intranasal system. When fentanyl is 
administered through buccal mucosa is rapid, providing 
significant pain relief within 15-30 minutes [5]; on the 
other hand, intranasal fentanyl spray can produce a 
Steps and pain 
intensity 
(scale: 1-10) 








Hydrocodone, oxycodone, tramadol 
(± non opioid analgesics)           
(± adjuvants) 
Severe pain     
(7-10) 
Hydromorphone, fentanyl, 
methadone, oxycodone (±nonopioid 
analgesics) (± adjuvants) 
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substantial reduction of BTP as soon as 15 minutes after it 
is taken [6].  
Frequent exacerbations of pain intensity could be the sign 
of inadequate baseline analgesic therapy (beyond 
disease’s progression). Moreover it has been 
demonstrated that there are individual variations in 
morphine absorption or alterations in its volume of 
distribution; these findings could explain the relationship 
between the variation of opioid’s plasmatic concentration 
during the day, which depends on the individual,  and the 
analgesic activity.  
In addition to this, the physicians underline the great 
variability in patient’s response to opioids and the need to 
individualize opioids’ use: patients differ in drug’s 
sensibility (some of them need higher doses to gain the 
same outcome) and show different responses to different 
opioids. 
Finally, we know that cross-tolerance among opioids is 
incomplete and the conversion from an opioid to a 
different one can be difficult, because of the limits of 
equianalgesic tables[7]. 
Concerning the molecular aspects, there are many issues 
that influence patient’s response to opioid therapy: the 
receptor (polymorphism of the gene that codes receptor μ 
and beta-arrestine), the translation of intracellular 
signaling (role of regulator of G protein signaling protein 
family), the passage across the blood–brain barrier (G-
protein polymorphisms) and the metabolism (cytocrome 
P450) [8]. 
 
II. POLIMORPHISM OF MU OPIOID 
RECEPTORS 
Opioid receptors are widely distributed in central and 
peripheral nervous system. 
Three opioid receptors have been identified: μ, δ and κ. 
Morphine and other commonly used opioids, including 
oxycodone, hydromorphone, methadone and fentanyl, act 
primarily on the same target receptor, the μ-opioid 
receptor (MOR). In addition, oxycodone, hydromorphone 
and buprenorphine may have clinically important activity 
on other opioid receptors. The structure of the “μ opioid 
analgesics” ranges from minor variations of the morphine 
alkaloid structure, such as codeine, to markedly different 
structures, such as fentanyl and methadone [9]. 
These analgesics share the same general pharmacological 
profile as morphine, including analgesia, inhibition of 
gastrointestinal motility, and respiratory depression. 
However, differences in the clinical pharmacology of 
these μ receptor agonists seriously questioned: how might 
drugs that act on the same receptor differ so markedly?  
Nociceptive threshold varies depending on genic 
expression, as it was observed in animals lacking μ-
receptor (homozygotes), heterozygotes and carriers of the 
normal receptor. However, some allelic variants can 
modify the response to opioids maybe altering 
transcriptional factors.  Cytokines, in particular, are able 
to regulate some transcriptional factors and influence the 
activity of μ-receptor.  
The receptor μ has been cloned 15 years ago and it was 
named MOR-1; it is made of 4 exons. The physicians 
found out that giving antisense (a sort of an antibody 
which inactivates a part of the receptor) for exon 1, they 
obtained a reduction of the analgesic action of morphine 
but not of its active metabolite, morphine-6β-glucuronide 
(M6G). This event didn’t happen with antisense for exon  
2 and 3. 
Many variants of MOR have been discovered. For 
example, MOR-1A lacks of exon 4 which is partially 
transcribed on exon 3; in MOR-1B exon 4 is replaced by 
exon 5. Other variants differ for the intracellular terminus. 
It has been observed that, although the variants have 
similar affinity for morphine, they show differences in 
activating the receptor, that means a different efficacy 
[10]. 
Knockout methodology has been another useful tool. In 
this technique the gene is definitively deleted, while in the 
antisense technique mRNA is temporary inactivated. For 
example, the lack of the gene for MOR-1 prevents the 
action of morphine while other opioids retain the 
analgesic effect even though it is reduced.  
The hypothesis that retain of the analgesic effect depends 
on the link with other opioid’s receptors (such as δ and κ), 
has been rejected by the observation that residual 
analgesia was erased by MOR-selective antagonists. The 
pharmacological profile of M6G is similar to that of 
morphine and its analgesic effects are reversed by 
naloxonazine, a MOR-antagonist. However, the actions of 
M6G can be differentiated from morphine in several 
ways. Firstly, the antagonist 3-O-methylnaltrexone (3-
methoxynaltrexone) selectively blocks M6G-induced 
analgesia at doses that are ineffective against morphine. 
Secondly, M6G and several other drugs that act on the 
MOR retain their analgesic activity in CXBK mice, which 
are insensitive to morphine [11]. 
Genetic polymorphisms can also involve a single 
nucleotide (Single Nucleotide Polymorphism, SNP) in the 
DNA sequence of MOR’s gene (OPRM1). The most 
known mutation in this receptor is 118A > G SNP, a 
variant of 10-15% of caucasian people, where asparagine 
is replaced with aspartate on exon 1; this variation causes 
the loss of the glycosilation site on the extracellular 
terminus of MOR. This polymorphism is associated with 
a reduction of effects, above all of the side effects, of  
M6G, alfentanil and morphine. 
Homozygotes, unlike heterozygotes and normal 
genotypes, require higher doses of opioids to gain the 
same analgesic outcome. Moreover, patients with 118GC 
genotype require higher doses of morphine for post-
operative pain than patients with 118AG or AA genotype. 
Recently, the 118A>G genotype was associated with the 
level of pain control: homozygotes 118A showed a 
reduction in pain intensity greater than homozygotes 
118G and heterozygotes. However, these data are belittled 
by the observation that patients not responsive to 
morphine didn’t have a different genotype from 
responsive patients.  
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Moreover, also side effects could have a genetic 
explanation. For example, in volunteers nausea, vomit and 
respiratory depression were associated to 118A>G 
polymorphism and this polymorphism seemed to cause a 
general reduction of clinical effects of opioids and higher 
analgesic request [12]. 
Polymorphisms involved in opioid response are complex 
and multigenic, with a great number of alleles. 
Furthermore, some genetic variations interfere with the 
affinity between receptor and opioid and lead to a 
different activation e/o desensitization. 
For example, they can influence the transcription of beta-
arrestine, an intracellular protein involved in the process 
of receptorial desensitization and internalization. It was 
observed a genetic polymorphism for beta-arrestine in 
patients showing a phenotype with low analgesic response 
to morphine or prevalence of side effects morphine-
induced [13].  
 
III.     REGULATOR OF G-PROTEIN 
SIGNALING (RGS) 
MOR belongs to the G protein coupled receptor family, 
with an extracellular N terminus, an intracellular C 
terminus, and seven membrane-spanning domains in 
between that comprise the binding pocket for the drug.  
Heterotrimeric G proteins comprise three proteins: one 
Gα subunit and a heterodimer of β and γ subunits. MOR 
interacts with the Gαi/o class of adenylate cyclase 
inhibitory Gα proteins [14], that is comprised of Gαi and 
Gαo. In the resting state the Gα subunit is bound to the 
guanine nucleotide GDP and is in complex with the β and 
γ subunits. Activation of MOR by agonists leads to 
dissociation of GDP from the Gα subunit, which is 
replaced by GTP, and separation of the Gα-GTP from the 
βγ heterodimer. The now active Gα-GTP and βγ subunit 
complex interact with intracellular signaling proteins, 
including inwardly rectifying potassium channels, 
calcium channels, phospholipase C and the mitogen-
activated protein kinase (MAPK) pathway as well as a 
variety of adenylate cyclase isoforms, to generate 
physiological responses. The intracellular signal is 
terminated by endogenous GTPase activity of the Gα 
subunit which hydrolyzes the Gα bound GTP to GDP. 
Gα-GDP can no longer activate effector proteins and 
moreover re-associates with the βγ heterodimer to 
terminate βγ signaling and reform the GDP-bound 
heterotrimer. In this way, heterotrimeric G protein 
substrate can be recycled for a subsequent round of 
receptor activation. The enzymatic GTPase activity of the 
Gαi/o subunits is slow with a GTP turnover rate of 2–5 per 
minute. This is not sufficiently rapid to turn off the signal 
and allow responses to subsequent incoming signals. 
However, the rate of hydrolysis of GTP is accelerated 
approximately 100-fold by the binding of a regulator of G 
protein signaling (RGS) protein to the active GTP-bound 
Gα subunit. RGS proteins thus function as GTPase 
accelerating proteins (GAPs) and, by rapidly removing 
the active Gα-GTP and βγ species, act as negative 
regulators of G protein-coupled receptor (GPCR) 
signaling. Since RGS proteins negatively regulate GPCR 
signaling, these accessory proteins have been implicated 
in the actions of opioids [15].  
There are more than 30 mammalian RGS proteins, 
defined by the presence of a RGS homology (RH) 
domain, a region of 125 aminoacids that binds the Gα-
GTP subunit and accelerates GTP hydrolysis. RGS 
proteins are divided into several families based on the RH 
domain homology and on the existence of a variety of 
additional structural domains. Consequently, it is difficult 
to identify the individual RGS protein or proteins that 
might be specifically responsible for the negative 
modulation of opioid signaling in a given tissue and 
therefore relevant to a particular physiological response. 
Certainly, there are so many RGS proteins that 
redundancy is likely. For example, RGS2, RGS4, RGS6, 
RGS7, RGS8, RGS9-2, RGS11, RGS19 and RGS20 have 
all been reported to act as GAPs for MOR signaling in 
different systems. Therefore, it is difficult to ascertain if 
an observed lack of physiological effect in response to 
knockdown or knockout of a single RGS protein is 
meaningful.  
There are currently no useful pharmacological inhibitors 
of RGS proteins available with which to probe roles for 
these proteins, although progress is being made in this 
area [17]. 
 
IV.           P-GLYCOPROTEIN 
The membrane-bound drug transporter P-glycoprotein 
influences drug absorption and drug excretion. It regulates 
the transfer of opioids across the blood–brain barrier and 
can actively pump opioids out of the central nervous 
system (CNS). P-glycoprotein knockout mice, which are 
completely devoid of P-glycoprotein activity, have 
enhanced absorption and high CNS concentrations of P-
glycoprotein substrates (e.g. morphine, fentanyl, and 
methadone) with associated prolongation of analgesia. 
Administration of cyclosporin, a P-glycoprotein inhibitor, 
results in increased fentanyl and morphine-induced 
analgesia. Interindividual variability in P-glycoprotein 
activity is well recognized and genetic variations in the 
multidrug resistance gene (MDR-1), which encodes for P-
glycoprotein, have been associated with resultant 
alterations in P-glycoprotein activity [18]. 
Since P-glycoprotein modulation of opioid CNS levels 
varies substantially among different opioids, the effects of 
genetic variation altering P-glycoprotein activity are 
different, depending on the opioid in question. MDR-1 
gene is therefore a good candidate gene for influencing 
the analgesic response to opioids and the prevalence of 
opioid-induced CNS side effects. Whereas SNPs have 
been identified in the MDR-1 gene: two mutations 
(C3435T and G2677T/A) have been associated with 
differences in P-glycoprotein expression or function. A 
variation in the G2677T/A genotype has also been shown 
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V.       P450- CYTOCROME 
As for the genetic variations of opioid receptors, also the 
enzymes involved in drugs’ metabolism can influence the 
response to opioids. All opioids are metabolized mainly 
by P450-Cytocrome and for a lesser extent by UDP-
glucuronosiltransferase (UGT). 
Although CYP3A4 is involved in the metabolism of many 
opioids, CYP2D6 shows a greater genetic instability and 
it is involved in generating strong metabolites with a 
greater affinity for μ-receptor. On the other hand, 
functional effects of genetic variants of UGT have not 
been defined yet. 
The CYP2D6 gene is highly polymorphic, with 
approximately one hundred of identified allelic variants; 
among these variants some have a deleted function, some 
have a reduced function, some others are duplicated and 
so they have an increased function. The main substrates of 
this enzyme are: benzodiazepines, haloperidol, 
carbamazepine, fentanyl, alfentanil and methadone, 
antifungal agents, many antibiotics, calcium antagonists, 
antihistamines, antiarrhythmics, steroids and 
immunosupressants. This wide range of drugs is the main 
reason of a great possibility for a competitive interaction, 
which depends on drugs’ concentration, affinity between 
enzyme and substrate, contemporary administration of 
drugs that induce the enzyme [20]. 
 
VI. TOLERANCE 
Side-effects and analgesic responses can vary 
significantly among patients. Although all MOR-agonists 
are associated with tolerance after repeated usage and 
exhibit cross tolerance to each other, the degree of cross 
tolerance varies widely. Indeed, we use incomplete cross 
tolerance to restore analgesic sensitivity in highly tolerant 
patients. When switching a patient who is highly tolerant 
to one MOR-selective opioid into another opioid, a 
process that is termed “opioid rotation”, analgesia is often 
restored by the second drug at doses ≥ 50% below the 
predicted equivalent dose determined by relative potency 
studies in naive subjects. Many issues could play a role in 
incomplete tolerance, including metabolism and 
pharmacokinetics and MOR multiplicity [21]. 
Moreover, incomplete cross tolerance can depend on 
differences in agonistic efficacy. The effect of an opioid 
depends on the number of filled receptors: the more they 
are filled, the less intrinsic activity the opioid has got. 
Therefore, if the receptorial reserve is great, the intrinsic 
efficacy of that opioid will be great. 
For example, on the one hand morphine is an agonist with 
low intrinsic activity and has to fill many receptors, so it 
is associated with high degree of tolerance; on the other 
hand methadone needs to fill a lower number of receptors 
to obtain the same outcome. That’s the reason why the 
switching from an opioid which is loosing its analgesic 
properties to an opioid with greater efficacy, can help us 




VII.          HYPERALGESIA 
Many studies have demonstrated that opioids can 
unexpectedly produce an increased response to a painful 
stimulus (hyperalgesia) or a painful response to a 
harmless stimulus (allodynia). This phenomenon can 
develope in response to both chronic and acute exposure 
to opioids. In patients with chronic pain the 
administration of repeated doses of opioids gradually 
reduces the threshold of response to nociceptive stimuli. 
This status can lead the patient to a condition of 
subliminal withdrawal (because of the low plasmatic 
concentration among the doses) and to the increase of 
progressive neuronal discharge and the further reduction 
of nociceptive threshold [22]. The clinical consequence is 
the loss of analgesic efficacy. Therefore the reduction of 
analgesic efficacy can depend on many issues such as 
tolerance, hyperalgesia or progression of the disease . 
Moreover, antinociceptive system is balanced by 
pronociceptive system (hypothesis of Celerier) [23]. So 
what happens when starting a therapy with opioids? The 
pronociceptive system gets upregulated and, in order to 
reach a new balance, the fisiologic excitatory response 
opposes to the inhibitory action of opioids. Clinically the 
patient will complain of hyperalgesia until a new balance 
in neuronal activity will be reached. 
 
VIII. CONCLUSION 
Opiates play a basic role in the management of pain. The 
treatment of pain requires individualization of therapy 
because of the wide range of responses of patients to 
individual drugs [24]. 
Frequent events of BTP can result from inadequate daily 
therapy. The dosage of opioids will be considered 
satisfactory when the patient will have less than 2-3 
events of BTP a day. A better management of the 
scheduled doses can further reduce the events of BTP. 
There is no ceiling effect for analgesia and doses can be 
escalated until limiting side effects are reached, at which 
point patients can be switched to an alternative opioid. 
Incomplete cross-tolerance can explain the utility of 
opioid rotation. Most clinical analgesics act through μ 
receptors. Recent studies now indicate that there is a great 
number of splice variants of this receptor. Pharmacologic 
differences among these variants may help to explain 
differences in the actions of various opioids despite the 
fact that they all are MOR-selective. Differences in the 
generation of these variants may also help to explain the 
wide genetic variability of response among patients taking 
these drugs and may provide insights into why clinicians 
still need to individualize therapy for their patients. 
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